Premature birth
Drug research and approvals for premature birth: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 419 studies of premature birth are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 419
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight InfantsNCT07950774 · Not reported · University of Stellenbosch · starts Dec 1, 2026
- Safety and Effectiveness of Different Interface Models for Non-invasive Ventilation Support for Preterm Newborns With a…NCT07944794 · Not applicable · University of Sao Paulo General Hospital · starts Sep 19, 2025
- Exploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's NeurodevelopmentNCT07943130 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Aug 25, 2026
- NAVA Use in Preterm Neonates With Respiratory Distress SyndromeNCT07926009 · Not applicable · Ain Shams University · starts Jan 24, 2026
- Autologous Hair Follicle-Derived Secretome and Platelet-Rich Plasma for Premature Ovarian InsufficiencyNCT07916740 · Phase 2 · Trio Fertility · starts Sep 11, 2025
- Maximising Maternal Milk for Preterm InfantNCT07908238 · Not applicable · National Maternity Hospital, Ireland · starts Nov 7, 2025
- Impact of Higher Zinc Supplementation on Neonatal Weight VelocityNCT07896070 · Phase 4 · Augusta University · starts Aug 1, 2026
- Nutritional Maturity in Preterm Newborns (Premature Infant Oral Motor Intervention, PIOMI)NCT07894380 · Not applicable · Ataturk University · starts Feb 1, 2026
- AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)NCT07859020 · Not reported · Inha University Hospital · starts Dec 1, 2023
Approved 2
- Hydroxyprogesterone caproateProgesterone receptor agonist
- AtosibanOxytocin receptor antagonist
Phase 3 12 of 18
- ProgesteroneProgesterone receptor agonist
- NifedipineVoltage-gated L-type calcium channel blocker
- RetosibanOxytocin receptor antagonist
- IndomethacinCyclooxygenase inhibitor
- Epoetin betaErythropoietin receptor agonist
- DydrogesteroneProgesterone receptor agonist
- AzithromycinBacterial 70S ribosome inhibitor
- CaffeineAdenosine receptor antagonist
- Nitric oxideSoluble guanylate cyclase activator
- GentamicinBacterial 70S ribosome inhibitor
- PyrimethamineDihydrofolate reductase inhibitor
- SulfadoxineDihydropteroate synthetase inhibitor
Phase 2 12 of 23
- SildenafilPhosphodiesterase 5A inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- Bucelipase alfa
- Castor oil
- MetoprololBeta-1 adrenergic receptor antagonist
- MisoprostolProstanoid EP3 receptor agonist
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- MorphineMu opioid receptor agonist
- Insulin humanInsulin receptor agonist
- Epoetin alfaErythropoietin receptor agonist
- SulfasalazineArachidonate 5-lipoxygenase inhibitor
- DopamineBeta-1 adrenergic receptor agonist
Phase 1 or earlier 12 of 14
- RemifentanilMu opioid receptor agonist
- IbuprofenCyclooxygenase inhibitor
- KetoconazoleCytochrome P450 51 inhibitor
- MethadoneMu opioid receptor agonist
- MoxifloxacinTopoisomerase IV inhibitor
- LidocaineSodium channel alpha subunit blocker
- ErgocalciferolVitamin D receptor agonist
- TheophyllinePhosphodiesterase 4 inhibitor
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- GabapentinVoltage-gated calcium channel modulator
- LactuloseColonic bacteria substrate
- Fospropofol
How its trials ended
2,324 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 411 whose ending is known, 34% met their primary endpoint, 15% missed it and 51% stopped early.
- Completed, result not reported1,02544%
- Ongoing46720%
- Status unknown42118%
- Met its primary endpoint1386%
- Stopped: other or unclear1205%
- Stopped: enrollment or feasibility663%
- Missed its primary endpoint623%
- Stopped: lack of efficacy10<1%
- Stopped: sponsor or business decision9<1%
- Stopped: funding4<1%
- Stopped: safety2<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA